arrow
T

Takashi Kojima

National Cancer Center Hospital East
H指数:47
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

First-line tislelizumab plus chemotherapy versus placebo plus chemotherapy in unresectable advanced/metastatic esophageal squamous cell carcinoma: minimum 3-year survival follow-up of a randomized phase 3 trial (RATIONALE-306)

一线替雷利珠单抗联合化疗对比安慰剂联合化疗在不可切除的局部晚期/转移性食管鳞状细胞癌中的应用:一项随机III期试验(RATIONALE-306)3年生存随访的最低数据

2026-09-030
OAAI
Sparfloxacin reveals a host–virus dual-target antiviral scaffold against respiratory syncytial virus

司帕沙星揭示了一种针对呼吸道合胞病毒的主-病毒双靶点抗病毒骨架

2026-08-080
OA
Pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer: 5-year extended follow-up for the randomized phase III KEYNOTE-590 study

帕博利珠单抗联合化疗与化疗对比治疗晚期食管癌:KEYNOTE-590随机III期研究的5年扩展随访

2025-11-180
OAAI
Characterization of early-onset gastritis during zolbetuximab-containing chemotherapy in CLDN18.2-positive gastric cancer

CLDN18.2阳性胃癌患者接受含zolbetuximab化疗期间早期胃炎的特征分析

2025-09-300
OAAI
First-Line Tislelizumab Plus Chemotherapy for Esophageal Squamous Cell Carcinoma with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-306

一线Tislelizumab联合化疗治疗程序性死亡配体1表达 ≥ 1% 的食管鳞状细胞癌: 原理306的回顾性分析

2025-03-010
OAAI
Prognostic and predictive factors for the efficacy and safety of trastuzumab deruxtecan in HER2-positive gastric or gastroesophageal junction cancer

曲妥珠单抗deruxtecan治疗HER2-positive胃癌或胃食管交界处癌的疗效和安全性的预后和预测因素

2024-11-020
OAAI
Multiomic molecular characterization of the response to combination immunotherapy in MSS/pMMR metastatic colorectal cancer
2024-02-084
OAAI
Comprehensive single-cell analysis demonstrates radiotherapy-induced infiltration of macrophages expressing immunosuppressive genes into tumor in esophageal squamous cell carcinoma

全面的单细胞分析表明,放疗诱导的表达免疫抑制基因的巨噬细胞浸润到食管鳞状细胞癌的肿瘤中

2023-12-159
OAAI
Atezolizumab following definitive chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma
2023-11-010
OA
Transposable elements potentiate radiotherapy-induced cellular immune reactions via RIG-I-mediated virus-sensing pathways

转座因子通过rig-i介导的病毒感应途径增强放射治疗诱导的细胞免疫反应

2023-08-057
OAAI
A Single-Arm Confirmatory Study of Definitive Chemoradiation Therapy Including Salvage Treatment for Clinical Stage II/III Esophageal Squamous Cell Carcinoma (JCOG0909 Study)
2022-11-0132
PRE